Community poverty level influences time to first pediatric rheumatology appointment in Polyarticular Juvenile Idiopathic Arthritis

被引:7
|
作者
Balmuri, Nayimisha [1 ,2 ]
Soulsby, William Daniel [3 ]
Cooley, Victoria [2 ]
Gerber, Linda [2 ]
Lawson, Erica [3 ]
Goodman, Susan [1 ,2 ]
Onel, Karen [1 ,2 ]
Mehta, Bella [1 ,2 ]
机构
[1] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA
[2] Weill Cornell Med, New York, NY 10065 USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
关键词
HEALTH DISPARITIES; RADIOGRAPHIC PROGRESSION; SOCIOECONOMIC MEASURES; DISEASE OUTCOMES; CHILDREN; CARE; ACCESS; DELAY;
D O I
10.1186/s12969-021-00610-5
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: The impact of social determinants of health on children with polyarticular juvenile idiopathic arthritis (pJIA) is poorly understood. Prompt initiation of treatment for pJIA is important to prevent disease morbidity; however, a potential barrier to early treatment of pJIAs is delayed presentation to a pediatric rheumatologist. We examined the impact of community poverty level, a key social determinant of health, on time from patient reported symptom onset to first pediatric rheumatology visit among pJIA patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. Methods: This is a cohort study of pJIA patients in the CARRA registry who lived in the United States from July 2015-February 2020. The primary exposure was community poverty level derived by geocoding patient addresses. The primary outcome was time to first rheumatology appointment. Kaplan-Meier analysis was performed to analyze time to first rheumatologist visit, stratified by community poverty and family income. Log-rank tests were used to identify differences between groups. Adjusted cox proportional-hazards models were used to determine the relationship between community poverty level and time from onset of disease symptoms to date first seen by rheumatologist. Results: A total of 1684 patients with pJIA meeting study inclusion and exclusion criteria were identified. Median age of onset of pJIA was 7 years (IQR 3, 11), 79% were female, 17.6% identified as minority race and/or ethnicity, and 19% were from communities with >= 20% community poverty level. Kaplan-Meier analysis by community poverty level (< 20% vs >= 20%) yielded no significant differences with time to initial presentation to a pediatric rheumatologist (p = 0.6). The Cox proportional hazards model showed that patients with >= 20% community poverty level were 19% less likely (adjusted HR 0.81, 95% CI 0.67-0.99, p = 0.038) to be seen by a rheumatologist compared to patients with < 20% community poverty level, at the same time point, after adjusting for sex, race/ethnicity, insurance, education level, morning stiffness, RF status, and baseline CHAQ. Conclusion: In this study of pJIA patients in the CARRA registry, increased community poverty level is associated with longer time to presentation to a pediatric rheumatologist after symptom onset.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] LONG-TERM SAFETY OF ADALIMUMAB TREATMENT IN PEDIATRIC PATIENTS WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS AND ENTHESITIS-RELATED ARTHRITIS
    Ruperto, N.
    Lovell, D. J.
    Kingsbury, D. J.
    Burgos-Vargas, R.
    Imagawa, T.
    Horneff, G.
    Quartier, P.
    Goodman, S. I.
    Reiff, A.
    Giannini, E. H.
    Cardoso, A.
    Anderson, J. K.
    Varothai, N. A.
    Kalabic, J.
    Martini, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 610 - 611
  • [32] Cumulative Damage in Juvenile Idiopathic Arthritis: A Multicenter Study From the Pediatric Rheumatology Arab Group
    Al-Mayouf, Sulaiman M.
    Hashad, Soad
    Khawaja, Khulood
    Alrasheedi, Abeer
    Abdwani, Reem
    Abushhaiwia, Awatif
    AlSuwaiti, Muatasem
    Alzyoud, Raed
    AL Abrawi, Safiya
    Asiri, Abdulrahman
    Alshaikh, Manal
    Sharif, Elsadeg
    Muzaffer, Mohammed
    Alsewairi, Wafa
    Zlenti, Mabruka
    Kawaja, Ebtisam
    Almutairi, Muna
    Majeed, Mahmoud
    Lotfy, Hala
    AlMarri, Munira
    Almutairi, Nora
    ARTHRITIS CARE & RESEARCH, 2021, 73 (04) : 586 - 592
  • [33] Population Health Management for Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network
    Harris, Julia
    Bingham, Catherine
    Vora, Sheetal
    Yildirim-Toruner, Cagri
    Ferraro, Kerry
    Friedrichsen, Erik
    Bullock, Danielle
    Burnham, Jon
    Lee, Tzielan
    Lovell, Daniel
    Wimmel, Ted
    Mincarelli, Delores
    Patil, Mayur
    Phillips, Magen
    Morgan, Esi
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 5311 - 5312
  • [34] Are We Meeting Benchmarks for Wait Times to Pediatric Rheumatology Care for Juvenile Idiopathic Arthritis (JIA)?
    Barber, Claire
    Shiff, Natalie
    Barnabe, Cheryl
    Benseler, Susanne
    Chin, Ricky
    Johnson, Nicole
    Luca, Nadia
    Miettunen, Paivi
    Twilt, Marinka
    Veeramreddy, Dwaraka
    Schmeling, Heinrike
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [35] Turkish Pediatric Rheumatology Society consensus statements on systemic onset juvenile idiopathic arthritis in Turkey
    Sozeri B.
    Ayaz N.A.
    Turgay S.
    Makay B.
    Demirkaya E.
    Unsal E.
    Kasapcopur O.
    Ozen S.
    Pediatric Rheumatology, 13 (Suppl 1)
  • [36] Diagnosis of juvenile idiopathic arthritis in the first level of care: in relation to a case
    Martinez Munoz, Gonzalo Eleodoro
    Martinez Saltos, Ana Belen
    Paguay Moreno, Angel Ramiro
    REVISTA CUBANA DE REUMATOLOGIA, 2019, 21 (01):
  • [37] Variability of Data Completeness and Consensus Treatment Plan Adherence for Polyarticular Juvenile Idiopathic Arthritis Patients Within the Childhood Arthritis and Rheumatology Research Alliance Registry
    Glaser, Daniel
    Yildirim-Toruner, Cagri
    Tarvin, Stacey
    Ardoin, Stacy
    Beukelman, Timothy
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 765 - 767
  • [38] Cost-Effectiveness Analysis of First-Line Treatment With Biologic Agents in Polyarticular Juvenile Idiopathic Arthritis
    Luca, Nadia J.
    Burnett, Heather F.
    Ungar, Wendy J.
    Moretti, Myla E.
    Beukelman, Timothy
    Feldman, Brian M.
    Schwartz, Gwen
    Bayoumi, Ahmed M.
    ARTHRITIS CARE & RESEARCH, 2016, 68 (12) : 1803 - 1811
  • [39] Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations
    Leu, Jocelyn H.
    Shiff, Natalie J.
    Clark, Michael
    Bensley, Karen
    Lomax, Kathleen G.
    Berezny, Katherine
    Nelson, Robert M.
    Zhou, Honghui
    Xu, Zhenhua
    PEDIATRIC DRUGS, 2022, 24 (06) : 699 - 714
  • [40] Protocols on classification, monitoring and therapy in children’s rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis
    Gerd Horneff
    Ariane Klein
    Gerd Ganser
    Michaela Sailer-Höck
    Annette Günther
    Ivan Foeldvari
    Frank Weller-Heinemann
    Pediatric Rheumatology, 15